Northern Trust’s Enveric Biosciences ENVB Stock Holding History

Northern Trust’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4	Closed	-$8K	–	4731
2022 Q2	$8K	Hold	4	–	–	﹤0.01%	4707
2022 Q1	$12K	Hold	4	–	–	﹤0.01%	4693
2021 Q4	$34K	Hold	4	–	–	﹤0.01%	4647
2021 Q3	$76K	Hold	4	–	–	﹤0.01%	4466
2021 Q2	$87K	Buy	4 +3	+300%	+$64.3K	﹤0.01%	4400
2021 Q1	$34K	Buy	+1	New	+$34.9K	﹤0.01%	4412

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust's ENVB Position: Q3 2022 in Review

Northern Trust sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 4 shares — an estimated $8K sold.

Northern Trust first reported a position in ENVB in Q1 2021 and held it in 6 quarters. The position peaked at $87K in Q2 2021. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

Northern Trust reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
Northern Trust sold 4 Enveric Biosciences shares in Q3 2022, an estimated $8K.
Northern Trust first reported a position in Enveric Biosciences in Q1 2021 and held it in 6 quarters.
Northern Trust's Enveric Biosciences position peaked at $87K in Q2 2021.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Northern Trust's 13F filing for Q3 2022, filed 14 Nov 2022.